Publications

September 2005 (Revised June 2006)
Case

WuXi PharmaTech

By: Richard G. Hamermesh and Simin Zhou

WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details

Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China

February 2003 (Revised August 2005)
Case

UCB (A): Managing Information for Globalization and Innovation

By: F. Warren McFarlan and Brian DeLacey

This case presents a complex total MIS strategy case for a $3 billion European pharmaceutical/chemicals company based in Brussels. It covers corporate strategy alignment of IT portfolio, IT operations issues, and global coordination of IT. View Details

Keywords: Information Technology; Operations; System; Corporate Strategy; Investment Portfolio; Globalization; Pharmaceutical Industry; Pharmaceutical Industry; Brussels

August 2001 (Revised March 2008)
Case

Helios Health (A)

By: Regina E. Herzlinger and Alfred Martin

Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details

Keywords: Entrepreneurship; Price; Health Care and Treatment; Information Publishing; Innovation and Invention; Product Marketing; Demand and Consumers; Pharmaceutical Industry; Pharmaceutical Industry

Find at Harvard

13 Jul 2020
Research & Ideas

Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk

As chairman and CEO of the leading vaccine producer in the world, pharmaceutical giant Merck & Co., Ken Frazier has one of the highest-profile positions in global business. But Frazier, who is leading one of the firms on a charge to... View Details

Keywords: by Staff; Pharmaceutical

January 2017
Case

Medtronic: Making the Big Leap Forward (A)

By: William W. George and Monica Baraldi

In 2014, Medtronic was about to execute a $50 billion acquisition of Ireland-based Covidien. Medtronic CEO Omar Ishrak was committed to building the largest medical technology company in the world while broadening its ability to fulfill its mission of “alleviating... View Details

Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States

Article

What to Know About Locating in a Cluster

By: Willy C. Shih and Sen Chai

As a study of two industry clusters in Denmark shows, factors that can make clusters attractive—easy people movement and knowledge spillovers—can also make it harder for individual companies to retain proprietary knowledge. View Details

Keywords: Clusters; Clustering; Competitiveness; Life Sciences; Telecommunications; Science-based; Research And Development; Industry Clusters; Research; Innovation Strategy; Innovation and Management; Geographic Location; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Denmark

Register to Read

April 2014 (Revised July 2015)
Case

Sanofi Pasteur: The Dengue Vaccine Dilemma

By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud

In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details

Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France

November 2009 (Revised December 2009)
Case

GTC Biotherapeutics: Developing Medicines in the Milk of Goats

By: Ray A. Goldberg and Sarah Morton

GTC is the first company in the animal world to receive FDA approval of a transgenic pharmaceutical. What are the implications for other firms in plants and animals and their opportunities to produce new medicines in an economical and safe fashion? View Details

Keywords: Health Care and Treatment; Animal-Based Agribusiness; Plant-Based Agribusiness; Science-Based Business; Medical Specialties; Product; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry; United States

18 Jun 2001
Research & Ideas

When In-House Research Isn’t Enough

paradigm to consider that takes into account both internal and external research and development efforts to create what he calls a "company innovation system." "What I hope this term will convey," he told HBS alumni, "is what I'm seeing in... View Details

Keywords: by Jim Aisner

November 1991 (Revised August 2005)
Case

Whelan Pharmaceuticals: Tax Factors and Global Site Selection

Whelan Pharmaceuticals, a U.S. company with $3 billion in sales, must decide where to manufacture its newest product. In considering possible sites, both foreign and U.S., the firm must identify and make trade-offs between tax, marketing, and manufacturing factors. View Details

Keywords: Globalized Firms and Management; Geographic Location; Cost vs Benefits; Production; Pharmaceutical Industry; United States

August 1995 (Revised June 1997)
Case

Hillcrest Research Associates, Inc.

Hillcrest designs and administers testing procedures for drugs to determine whether they pass FDA specifications. As the company grows, it encounters problems with information technology and with the clinical research associates, who feel pressured to report more... View Details

Keywords: Growth Management; Information Technology; Health Testing and Trials; Pharmaceutical Industry

Find at Harvard

02 Oct 2000
Research & Ideas

The Dubious Logic of Global Megamergers

Williams had nearly $8 billion in sales. The oil industry is becoming more competitive in part because of such cast-off purchases by companies like Williams. Stay Home. For many companies, it still makes a lot more sense to grow... View Details

Keywords: by Pankaj Ghemawat & Fariborz Ghadar

15 Feb 2000
Research & Ideas

The Right Connections

pharmaceutical companies — what the authors call downstream social capital — had a direct impact on the size of the startup's IPO. "Downstream social capital was essential in attracting the interest of... View Details

Keywords: by Judith A. Ross

24 Sep 2013
First Look

First Look: September 24

models a negotiation between two pharmaceutical companies-Johnson & Johnson and Merck-concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract,... View Details

Keywords: Sean Silverthorne

June 2024
Supplement

Legacy Partners (A)

By: Richard S. Ruback and Royce Yudkoff

Instructors should consider the timing of making videos available to students, as they may reveal key case details.

Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details

12 Apr 2010
Research & Ideas

One Report: Better Strategy through Integrated Reporting

electronics company Philips; the Danish pharmaceutical company Novo Nordisk; the Brazilian cosmetics company Natura; and the U.S.-based... View Details

Keywords: by Martha Lagace

08 Aug 2017
First Look

First Look at Research and Ideas, August 8, 2017

trials at Boston Children’s Hospital. As the founders prepare to bring their new medical device to market, they struggle with two key decisions: Should Luminopia create its own salesforce to sell its product or should it outsource? And how should the View Details

Keywords: Sean Silverthorne

April 2017
Supplement

Imprimis (D)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details

Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States